Know Cancer

or
forgot password

Intraperitoneal Floxuridine in Gastric Carcinoma


Phase 1/Phase 2
N/A
N/A
Not Enrolling
Both
Stomach Neoplasms

Thank you

Trial Information

Intraperitoneal Floxuridine in Gastric Carcinoma


Dose of intraperitoneal FUDR 3000 mg/day x 3 days per cycle (2 cycles total, 2 weeks apart)

Inclusion Criteria


- Resectable gastric cancer beyond stage T1N0M0

- Normal organ function (marrow, kidneys, liver)

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Safety of intraperitoneal FUDR

Outcome Description:

This protocol is testing the safety of giving two cycles of intraperitoneal FUDR followed by the conventional postoperative chemo-radiation for gastric cancer

Outcome Time Frame:

three months after surgery

Safety Issue:

Yes

Authority:

United States: Food and Drug Administration

Study ID:

2150

NCT ID:

NCT00058916

Start Date:

September 2002

Completion Date:

December 2009

Related Keywords:

  • Stomach Neoplasms
  • Neoplasms
  • Carcinoma
  • Stomach Neoplasms

Name

Location

New York University School of MedicineNew York, New York  10016
University of Southern CaliforniaLos Angeles, California  90033